CpG island methylation status of miRNAs in esophageal squamous cell carcinoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Previous studies on esophageal squamous cell carcinoma (ESCC) indicated that it contains much dysregulation of microRNAs (miRNAs). DNA hypermethylation in the miRNA 5′ regulatory region is a mechanism that can account for the downregulation of miRNA in tumors (Esteller, N Engl J Med 2008;358:1148–59). Among those dysregulated miRNAs, miR‐203, miR‐34b/c, miR‐424 and miR‐129‐2 are embedded in CpG islands, as is the promoter of miR‐34a. We investigated their methylation status in ESCC by bisulfite sequencing PCR (BSP) and methylation specific PCR (MSP). The methylation frequency of miR‐203 and miR‐424 is the same in carcinoma and in the corresponding non‐tumor tissues. The methylation ratio of miR‐34a, miR‐34b/c and miR‐129‐2 is 66.7% (36/54), 40.7% (22/54) and 96.3% (52/54), respectively in ESCC, which are significantly higher than that in the corresponding non‐tumor tissues(p < 0.01). Quantitative RT‐PCR analysis in clinical samples suggested that CpG island methylation is significantly correlated with their low expression in ESCC, 5‐aza‐2′‐deoxycytidine (DAC) treatment partly recovered their expression in EC9706 cell line. We conclude that CpG island methylation of miR‐34a, miR‐34b/c and miR‐129‐2 are frequent events and important mechanism for their low expression in ESCC. DNA methylation changes have been reported to occur early in carcinogenesis and are potentially good early indicators of carcinoma (Laird, Nat Rev Cancer 2003;3:253–66). The high methylation ratio of miR‐129‐2 indicated its potential as a methylation biomarker in early diagnosis of ESCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A skin microRNA promotes differentiation by repressing ‘stemness’
Yi, R., Poy, M. N., Stoffel, M., & Fuchs, E. (2008) · Nature · doi:10.1038/nature06642 · Cited by 790 · cited 1×
“A recent study showed that miR-203 is closely related to the differentiation of stratified squamous epithelia.(23) Because of the function in decreasing cell proliferation, it was thought to be a tumor suppressor gene by now.”
BackgroundmiR-203 represses ‘stemness’ by repressing ΔNp63
Lena, A. M., Shalom-Feuerstein, R., di Val Cervo, P. R., Aberdam, D., Knight, R. A., Melino, G., & Candi, E. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.69 · Cited by 389
Cited by
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518
DNA methylation and microRNA dysregulation in cancer
Suzuki, H., Maruyama, R., Yamamoto, E., & Kai, M. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.07.007 · Cited by 271
The comprehensive landscape of miR-34a in cancer research
Li, S., Wei, X., He, J., Cao, Q., Du, D., Zhan, X., Zeng, Y., Yuan, S., & Sun, L. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09973-3 · Cited by 84
MiR‐129‐5p promotes docetaxel resistance in prostate cancer by down‐regulating CAMK2N1 expression
Wu, C., Miao, C., Tang, Q., Zhou, X., Xi, P., Chang, P., Hua, L., & Ni, H. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14050 · Cited by 28
Metadata
- Authors
- Chen, X., Hu, H., Guan, X., Xiong, G., Wang, Y., Wang, K., Li, J., Xu, X., Yang, K., & Bai, Y.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-08-24
- Volume
- 130
- Issue
- 7
- Pages
- 1607-1613
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1992106366
- Cited by
- 115
- References
- 2
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.